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EXCEPTIONAL CASE REPORT
A case of acute myeloid leukemia with promyelocytic features
characterized by expression of a novel RARG-CPSF6 fusion
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Although almost all cases of acute promyelocytic leukemia (APL) are associated with the t(15;17)
(q24;q21) translocation that creates the chimeric promyelocytic leukemia (PML)–RARA oncogene
(present in ;98%-99% of cases), alternative X-RARA fusions can initiate acute myeloid leukemia
(AML) with promyelocytic features.1 In both APL driven by PML-RARA and the AMLs driven by variant
RARA translocations, the DNA-binding, retinoid X receptor (RXR)-binding, and ligand-binding
domains of retinoic acid receptor (RAR) a (RARA) are preserved in the fusion proteins.2 RAR b
(RARB) and RAR g (RARG) are the 2 other RARs. The 3 RARs are highly homologous: they have
highly conserved DNA-binding and ligand-binding domains.3 Although uncommon, gene fusions
involving RARB (TBL1XR1-RARB) and RARG (PML-RARG and NUP98-RARG) have been reported
in cases of AML with promyelocytic features.4-6 As in the PML-RARA and X-RARA fusions, the RARB
and RARG fusions preserve the DNA-binding and ligand-binding domains of the RARs. We now
report a third gene fusion involving RARG, a RARG-CPSF6 fusion, in a patient with AML that
appeared to be typical APL by standard histopathology and immunophenotyping.
Case description
We report a patient presenting with AML with promyelocytic features without a detectable PML-RARA
fusion by routine cytogenetics, standard fluorescence in situ hybridization (FISH), or reverse transcription–
polymerase chain reaction (RT-PCR). The patient was a 26-year-old white man with no significant past
medical history who presented with a 2-week history of epistaxis, gingival bleeding, and petechiae. His
complete blood count showed a white blood cell (WBC) count of 16.4 3 109/L, hemoglobin of 10.5 g/dL,
and platelet count of 52 3 109/L. Review of the peripheral blood smear revealed numerous circulating
promyelocytes (81% of WBCs) and 3% circulating blasts, including many with Auer rods. The patient had a
consumptive coagulopathy. The diagnostic bone marrow biopsy aspirate had a differential of 60% blasts,
15% promyelocytes, 6% myelocytes, and 1% metamyelocytes (the core biopsy showed overall cellularity of
.90%). By morphology, review of the peripheral blood and bone marrow was consistent with the diagnosis
of hypergranular (or “typical”) APL (Figure 1A-B). The promyelocytes had enlarged, convoluted, oval to
irregularly shaped (including some bilobed or kidney-shaped) nuclei, dispersed chromatin, inconspicuous
nucleoli, and abundant dust-like azurophilic granules. These cells demonstrated strong and diffuse reactivity
to myeloperoxidase cytochemical staining, which often masked the nucleus and is characteristic of APL.
Flow cytometry performed on the bone marrow aspirate showed blasts comprising 53% of marrow
cellularity. The blasts were positive for CD33, CD13, CD64, CD117 (partial), and HLA-DR (weak). The
blasts were negative for CD34, CD56, CD19, CD2, CD5, CD123, CD14, CD11b, and terminal
deoxynucleotidyl transferase (TdT). Cytogenetic studies revealed an intermediate-risk karyotype of: 45, X,
2Y [10]/45, idem, add(6)(q?13) [2]/46, XY[8]. Given the concern for APL, the patient was immediately
treated with all-trans retinoic acid (ATRA); 713 chemotherapy (idarubicin and cytarabine) was started in
addition to ATRA on day 2.
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Figure 1. Histopathologic and genomic characterization of a case of AML with promyelocytic features. (A) Wright-Giemsa staining of the peripheral blood smear
highlighting promyelocytes (original magnification 3100). (B) Wright-Giemsa staining of the aspirate from the diagnostic bone marrow biopsy highlighting numerous blasts and
promyelocytes (original magnification 3100). The images were captured by an Olympus BX53 microscope with an Olympus UPlanSApo 1003/1.4 oil objective and an
Olympus DP26 digital camera with Olympus cellSens standard software (version 1.16; Tokyo, Japan). (C) Representative schematic of the main protein domains of RARG
isoform 1 (top), CSPF6 isoform 2 (middle), and the predicted RARG-CPSF6 fusion (bottom) with the fusion breakpoints highlighted in red (for RARG at amino acid 392 and
for CPSF6 at amino acid 231). Isoform choice was based on read support from the RNA-Seq data. (D) Schematic of the highly rearranged region on chromosome 12 where
the reciprocal inversion occurred. In panel D, regions A and K bookend regions B-J that were involved in distinct deletions or rearrangement events. The segments are not to
scale. (E) RNA-Seq reads based on a pseudo-alignment to the RARG-CPSF6 predicted fusion transcript. The coverage of reads uniquely aligned to the predicted fusion
(spanning the fusion breakpoint) is displayed in red on the top track in relation to the exons for the predicted fusion (bottom track). We observed only three reads supporting
wild-type RARG expression, which are likely indicative of a small number of contaminating benign cells.
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Standard AML molecular diagnostics were performed, and no other
prognostically significant mutations were identified. We performed
FISH with a RARA break-apart probe to detect X-RARA fusions,
which was negative. In an effort to identify a cryptic PML-RARA
fusion, we performed anti-PML immunostaining, which was normal.7
Given the absence of evidence of a RARA rearrangement, we
hypothesized that an alternative genetic mechanism was driving this
AML with promyelocytic features.
Methods
All sequencing runs were completed according the manufacturer’s
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Figure 2. Protein analysis and functional characterization of the RARG-CPSF6 gene fusion. (A) N-terminal and C-terminal anti-RARG antibodies were used to
probe immunoblots prepared from NB4 cells (an APL cell line), a t(15;17) APL sample, and a sample from our patient. Both experiments were repeated independently
with similar results. (B) Supervised hierarchical clustering of the top 500 dysregulated genes in t(15;17) APL (compared to all of the other non-t(15;17) AML cases
included in the TCGA AML analysis) clusters the case (bright red) with other APLs (dark red). (C) A schematic of the experimental platform (top). The Gal4-RARG*395
truncation did not activate the UAS-GFP reporter when treated with either ATRA or BMS961 (a RARG agonist). Gal4-RARG and Gal4-RARA both activated the UAS-
GFP reporter in response to ATRA, and this was not inhibited by coexpression of Gal4-RARG*395, indicating that the truncated RARG did not act as a dominant-negative
against RARA or RARG in this assay (* and § P values calculated by ANOVA with Bonferroni correction for multiple comparisons). This experiment was repeated
independently with similar results.
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version of our genome modeling system to complete the analysis
(supplemental Methods; supplemental Data Files 1-5).8
The UAS-GFP and Gal4 construct cotransduction experiments
were done as previously described. We created a truncated
RARG*395 based on whether the RARG transcript did not splice
into CPSF6 and translation read through into the intron (the next
codons are: g/gt gag tca tga, and tga stops) (see supplemental
Methods for the detailed methodology for western blotting, RT-PCR
validation, and cotransduction experiments).9
Results and discussion
We performed whole-genome sequencing (WGS) and RNA sequenc-
ing (RNA-Seq) on DNA and RNA isolated from bulk, cryopreserved cells
from the diagnostic bone marrow aspirate. We used DNA isolated from
a skin biopsy as the “normal/germ line” comparator for WGS. We
identified 9 total nonsilent coding somatic mutations (see supplemental
Table 1 and supplemental Figure 1 for copy number events). Mutations
in 3 of these genes (BMPR1A,NEAT1, andWT1) are thought to have a
role in leukemogenesis.10-12 Notably, 2 truncating mutations were
observed inWT1 (E340* and S1381*).WT1 has a complex pathogenic
role in AML but is recurrently mutated in 5.5% of AML cases overall and
is more common in APL (11%).10 We did not detect a PML-RARA or
X-RARA fusion. We did identify a highly rearranged region (including
multiple deletions, inversions, and intrachromosomal translocations) on
chromosome 12 with break points in the EIF4B, RARG, and CPSF6
genes. The rearrangement resulted in a fusion of RARG (in intron 9) to
EIF4B (in intron 8) and a deletion after intron 8 of EIF4B that then fused
into the intron leading into exon 6 ofCPSF6 (Figure 1C-D). This created
a novel RARG-CPSF6 in-frame fusion transcript, which was validated
by RNA-Seq read support as well as by RT-PCR followed by Sanger
sequencing (Figure 1E; supplemental Figure 2). The RARG-EIF4B
genomic rearrangement was also confirmed by PCR followed by
Sanger sequencing (supplemental Figure 3; supplemental Data File 6).
Immunoblotting with an N-terminal anti-RARG antibody or an anti-
CPSF6 antibody did not show clear evidence of an expressed RARG-
CPSF6 fusion protein (predicted at 78 kDa) (Figure 2A; supplemental
Figure 4). If the RARG-CPSF6 fusion protein was expressed, it would
have a C-terminal breakpoint disrupting the ligand-binding domain of
RARG rather than the N-terminal breakpoints that occur in the other
X-RAR fusions that preserve both the DNA- and ligand-binding domains
(Figure 1C).3-6
Using 178 samples from the TCGA AML cohort, we used a Student
t test to identify genes with significantly different expression in the
16 APL samples, which all harbored t(15;17), compared with the
other AML subtypes.13 The top 250 up- and downregulated genes
were selected to define a 500 gene APL signature. Hierarchical
clustering based on this signature grouped this case with the
t(15;17) APLs (Figure 2B; supplemental Data File 7). Next, we
performed in vitro cotransduction/transfection experiments using
a Gal4-RARG*395 truncation construct (the fragment of RARG
predicted to be expressed in the fusion) and a UAS-GFP reporter
plasmid (Figure 2C). The Gal4-RARG*395 truncation did not
activate the UAS-GFP reporter when cells were treated with either
ATRA or BMS961 (a RARG agonist), suggesting that our case is
ATRA-resistant. To determine whether the RARG*395 truncation
could act as a dominant-negative, we performed a cotransduction/
transfection experiment with truncated RARG and PPAR re-
sponse element (PPRE)-luciferase or ApoA1-luciferase reporters
in 293T cells. The expression of truncated RARG*395 neither
augmented nor inhibited the response to ATRA or to the RARG-
specific ligand BMS961, suggesting a null phenotype rather than
a dominant-negative phenotype (data not shown).
RARG has leukemogenic potential when fused to PML both in vitro14
and in vivo.5,15 In addition to PML-RARG, a NUP98-RARG gene
fusion has been reported in AML with APL-like morphologic and
immunophenotypic features.6,16,17 This is the first report of a case of
AML with promyelocytic features characterized by the expression of
a RARG-CPSF6 fusion. CPSF6 is a subunit of the cleavage and
polyadenylation specificity factor (CPSF) protein complex that is
involved in the processing of the 39 end of messenger RNA (mRNA)
precursors.18 mRNA processing may be important mechanistically
in AML with variant RAR translocations as FIP1L1-RARA fusions
have been reported, and FIP1L1 is also a subunit of the CPSF
complex.3 CPSF6 has been found to be a recurrent fusion partner in
myeloid/lymphoid neoplasms associated with eosinophilia.19,20 In our
case, the disruption of neighboring genes around the area of the
complex rearrangement event on chromosome 12 and the other
somatic mutations present could have contributed to the promyelo-
cytic phenotype. Moreover, we did not detect the presence of an
expressed RARG-CPSF6 fusion protein by immunoblotting. If the
RARG-CPSF6 fusion protein was expressed, the fragment of RARG
that is part of the fusion may not bind ligand given the truncation of the
ligand-binding domain and the results of our cotransduction/transfection
experiments. Future studies are needed to define the mechanisms by
which the RARG-CPSF6 gene fusion and/or the loss of endogenous
RARG expression (we did not detect significant WT RARG expression
by RNA-Seq or immunoblotting) contribute to leukemogenesis.
Note added in proof
During the revision of this manuscript, 2 studies were published
that identified cases of AML with promyelocytic features with
CPSF6-RARG fusions [Liu T, Wen L, Yuan H, et al. Blood. 2018;
131(16):1870-1873 and Qin YZ, Huang XJ, Zhu HH. Leukemia.
doi:10.1038/s41375-018-0095-z].
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